1. Top Tips in Evidence-Based Care for HFrEF

3. Typical Patient With HFrEF

4. Key Therapies in HFrEF: How Do They Work?

5. 2016 ESC HF Guidelines: Next...Add an MRA and ARNI

6. Principles for Successful Treatment for HF

7. Starting and Titrating Drug Therapies in HFrEF

8. ESC 2016 Guidelines: Classifications of HF

9. CHARM: Candesartan Reduced CV Death + Time to First HF Hospitalization in HFrEF and HFmrEF Categories

10. Benefit of ARNI in HFrEF: Primary Composite Endpoint -- CV Death and First HF Hospitalization

11. Additional Key Points: PARADIGM-HF

12. PARADIGM-HF: Benefit of ARNI in HFrEF to Reduce Time to First Hospitalization for HF Was Seen Very Early

13. Managing Diabetes in the Presence of HFrEF

14. SGLT2 Inhibitors: Use in Diabetes and HF

15. Ongoing Trials With SGLT2 Inhibitors in Patients With Diabetes and HF

16. Questions to Ponder and Points of Clarification: SGLT2 Inhibitors in HF

17. Altered Patient Scenario: Tachycardia in HFrEF

18. SHIFT Trial: Increased Risk of CV Death and HF Hospitalization With Increased Heart Rate in SR in HF

19. AF and HF

20. Heart Rate as a Predictor of Outcome in HF

21. Anticoagulation and AF in HF

22. Management of HF in the Inpatient Setting

23. PIONEER HF: Safety of ARNI -- Including ACE Inhibitor and ARB-Naive Patients With HFrEF

24. PIONEER HF: Exploratory Clinical Endpoints

25. Clarification of Terms -- What Do We Mean?

26. Conclusions

27. Abbreviations

28. Abbreviations (cont)

29. Abbreviations (cont)